PubMed HealthSearch

Biomedical subjects

W Oosterlinck

Publications and source records attributed to W Oosterlinck.

At least 19 recordsLinked to original sources

Factors affecting recurrence and progression in superficial bladder tumours.

Prognostic factors in superficial bladder tumours are highly correlated with each other. In this study, their relative importance is examined and grouping of patients in three different prognostic groups suggested. 576 patients (from EORTC protocols 30790 and 30782) were analysed. They have been followed from 3 months to 8.6 years with a median of 4 years. 76 patients developed an invasive tumour (> or = T2); the shortest time to invasion was 12 weeks, the longest was 6.6 years. Time from invasion to death ranged from 3 weeks to 4.4 years with a median of 2 years. Prognostic factors contributing to recurrence, invasion and survival were investigated: age, sex, size of largest tumour, number of tumours, T-category, G-grade, time from diagnosis (years), prior recurrence rate/year, site of involvement. The relative importance of these factors was measured by performing a multivariate analysis based on Cox's proportional hazards regression model. Based on the most important prognostic factors and their association with invasion and death, an index was computed reflecting the risk of both invasion and death due to malignant disease, respectively. The index was used to assign patients to one of three prognostic groups. Three main factors determined patient's prognosis: tumour size, G-grade and prior recurrence rate/year. The model coefficients for invasion were 0.51 (recurrence rate < 1/year, 1-3/year, > 3/year), 84 (grade 1, 2, 3), 0.48 (size < 1.5, 1.5-3, > 3 cm) and for death due to malignant disease 0.89 (recurrence rate), 0.73 (grade) and 0.44 (size), respectively. Risk groups are suggested based on the index. Additional treatment in patients with superficial transitional cell carcinoma of the bladder may be decided depending on the risk group to which the patient belongs.

Adolescent

Prognostic factors in advanced prostatic carcinoma treated with total androgen blockade. Flutamide with orchiectomy or with LHRH analogues. A Belgian multicentric study of 546 patients.

Prognostic factors were evaluated in advanced loco-regional (M0) or distant metastatic (M1) prostatic carcinoma treated with total androgen blockade (flutamide with either orchiectomy of LHRH-analogues), in 546 patients from a Belgian multicentric study. After a mean follow-up of 16.5 months (maximum 37 months) 113 (21%) patients had progressed (90 were patients with M1 disease (31%)). The estimated median progression-free survival exceeded 37.5 months. The results of a univariate analysis show that the following parameters are important prognostic factors with respect to progression-free survival in these patients: M stage, G grade, ECOG performance status, weight loss, concomitant disease, pain, dysuria and haemoglobin (Lee-Desu test, p < or = 0.01). From a multivariate analysis (Cox regression) the following prognostic factors were indicative of a decrease in progression-free survival: M1 stage, high initial G grade, ECOG performance status > I, high serum PSA, presence of concomitant disease, presence of pain and absence of dysuria. Age did not appear to be a statistically significant prognostic factor.

Aged

Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group.

The European Organization for Research and Treatment of Cancer genitourinary group has completed 2 parallel prospective randomized studies, one with 30 mg. mitomycin C and the other with 50 mg. doxorubicin as adjuvant intravesical treatment after transurethral resection of superficial transitional cell bladder carcinoma. These studies were designed to compare early (the day of resection) versus delayed (between 7 and 15 days after resection) instillations and short-term (6 months) versus long-term (12 months) treatment. The results indicate that in regard to recurrence rate patients having a delayed and short-term treatment do worse than those having early instillations (for 6 or 12 months) or those having prolonged treatment (either immediate or delayed). With an average followup of 4 years survival, progression beyond T1 disease, development of distant metastases and appearance of a second primary were not influenced by the therapeutic regimen. A multivariate analysis of prognostic factors is presented, which indicates that after adjustment for these factors, patients in the delay, no maintenance arm have a significantly higher recurrence rate than the other patients.

Administration, Intravesical

Physiopathology of renal colic and the therapeutic consequences.

NSAID are by far the most efficient therapy in renal colic treatment as they directly interfere with the physiopathology of a renal colic. Other therapies that have been standard are now shown to be insufficient or even contraindicated. Hydratation during a renal colic seems to be unimportant. The efficiency of stone-expulsive drugs has still to be proven.

Analgesics, Opioid

Chemolysis of calcium containing urinary calculi. A review.

A review of current literature and research on chemolysis of calcium containing urinary stones is made. The type of chemolytic solution is dependent upon the composition of the stone. Calcium phosphates can be desolved with Suby or Renadecin solution although it is often tedious and time consuming procedure. Calcium oxalate, the major urinary stone component, can not be dissolved by these solutions. EDTA and other strong calcium chelators cannot be used because of their local toxicity. Certain enzymes can digest the organic matrix of the stone. The indication to chemolysis of stones are rather restricted.

Calcium

Analysis of urinary calculi.

Urinary calculi are often small (< 5 mg) and can be composed of many very different constituents. The highly variable composition has lead to the development of many different methods of calculi analysis. In general the analytical methods can be divided in chemical and physical methods. Chemical methods are destructive and need several mg of sample. The smallest stones can not be analyzed with chemical methods. Qualitative and semi-quantitative chemical analysis methods are not accurate and can lead to clinical significant errors. Quantitative, instrumental, chemical analysis is accurate and makes no clinical significant errors, but these consume too much sample. None of the chemical methods of stone analysis makes it possible to distinguish the mineral constituents with similar chemical composition, e.g. the calcium phosphates, from one another and they usually can not identify "unexpected" stones. Physical methods need less sample than chemical methods and physical methods can distinguish the different minerals in the stones. Thermal analysis can give quantitative results but needs relatively much sample. Optical methods can analyze a few grains of stone but gives only qualitative results. Both methods can not be used to analyze an "unexpected" stone. Best suited methods for the analysis of calculi are X-ray diffractometry and IR spectroscopy. X-ray diffractometry can detect crystalline minerals in low concentrations. IR spectroscopy can detect both crystalline and amorphous minerals. Both methods can be used for semi-quantitative stone analysis and can analyze less than one mg of stone sample. X-ray diffractometry and IR spectroscopy are also the best methods to identify "unexpected" stone constituents.

Calcium Oxalate

Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review.

Once hormone resistance has been developed in metastasized prostate cancer, the main aim of therapy is to ensure quality of life. Total androgen blockade which neutralizes the androgens of adrenal origin provides a therapeutic modality which gives +/- 16% objective and +/- 50% subjective response during several months. The two drugs actual available in Belgium are flutamide and cyproterone acetate. Especially flutamide has been used for this purpose. As the number and intensity of side effects is low, this can be considered as a first choice treatment when prostate cancer escapes its first line therapy.

Androgen Antagonists

A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder.

A total of 431 eligible patients with solitary, primary or recurrent stages Ta and T1 transitional cell carcinoma of the bladder was included in a randomized multicenter trial to compare a single intravesical instillation of 80 mg. epirubicin with water given immediately after resection, with respect to the disease-free interval and recurrence rate. The interval to initial recurrence was significantly better in favor of the epirubicin group. After a mean followup of 2 years it became evident that the recurrence rate after a single epirubicin instillation was decreased by nearly half with the same trend being found in all subgroups examined. Toxicity was mainly restricted to bladder irritation in plus or minus 10% of the cases. Pathology review brought considerable changes in T category from stages T1 to Ta (53%). Changes in grade were less pronounced but nevertheless important.

Administration, Intravesical

A plea for cold biopsy, fulguration and immediate bladder instillation with Epirubicin in small superficial bladder tumors. Data from the EORTC GU Group Study 30863.

The sensitivity of cystoscopy to distinguish infiltrating from superficial bladder tumors is very high. Only 28 (5.6%) of 501 single tumors, which were considered to be superficial by the urologist at visual inspection, were found to be infiltrating on pathological examination. If the size of the tumor and/or the cytological grade are considered, one can further reduce the number of infiltrating tumors missed, but it was impossible to identify them all. The recurrence rate of tumors at the resection site 4 weeks after TUR suggests the importance of trauma of the bladder mucosa in promoting recurrence. A single instillation of Epirubicin immediately after TUR prevents implantation of tumor cells and reduces the recurrence rate to nearly 50%. A combination of cold forceps biopsy and fulguration may be the most reasonable treatment for small bladder tumors.

Administration, Intravesical

Watertight sutures with fibrin glue: an experimental study.

A rat model was developed to test the watertightness of sutures and used to evaluate the value of fibrin glue (Tissucol, Immuno France, Tisseel, Immuno U.S., Inc.) in making conventional sutures watertight. Fibrin glue raised the mean hydrostatic pressure to which the skin suture resisted from 9.1 to 26.3 cm H2O, thus indicating that it enhances suture watertightness immediately after surgery. After 3 and 6 days, the pressure was increased, respectively, from 24.8 to 47.9 and from 56.5 to 73.3 cm H2O. For bladder sutures, the results are comparable.

Animals

[Principles of wound healing as applied to urethra surgery].

The authors describe the physiology of wound-healing and the factors influencing wound-healing that may play a role in urethral surgery. They present the specific characteristics of wound-healing in each treatment for urethral strictures. This knowledge can help to choose the right treatment for each type of urethral stricture.

Humans

[End-to-end anastomosis of the urethra].

End-to-end anastomosis is perhaps the most physiological method to cure a stricture of the urethra, provided it is short and the rest of urethra is elastic enough to overbridge the gap without tension. A success rate of more than 90% can be expected in these circumstances.

Anastomosis, Surgical

Rationale for local toxicity of calcium chelators.

Calcium chelating agents, such as ethylenediaminetetraacetate are toxic to urothelium. Their capacity to form complexes with calcium ions, which is the basis for their chemolytical effectiveness, also determines their toxicity. A decrease of chemolytical effectiveness by prior saturation of the chelator with Ca2+ or by lowering the pH to levels unfavourable for calcium binding significantly diminishes tissue injury. Exchange of Mg2+ ions does not, however, diminish tissue damage. The clinical use of calcium ligands is therefore unsafe.

Animals

Low-voltage coagulation for welding sutures watertight: an experimental study.

A rat model was developed to test the watertightness of sutures. In this model it was proved that welding by use of low-voltage coagulation current did not improve on the watertightness obtained with conventional skin suturing. The mean leak pressure after welding was about 4.2 cm H2O, i.e. statistically significantly lower than the mean leak pressure of the conventional suture, which is 14.1 cm H2O. Neither addition of protein solder nor an additional conventional suture improved these results. It is therefore concluded that low-voltage coagulation is unsuitable for welding tissues.

Animals

Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group.

The anthracycline derivatives Adriamycin and 4-epirubicin are used to prevent recurrent tumors after transurethral resection of superficial bladder tumors. Both drugs are instilled intravesically. The present report describes the results of two multicenter, prospective, randomized phase III studies carried out by the EORTC GU Group. In protocol 30,790, after a mean follow-up period of 26.6 months, the recurrence rate for 165 patients treated with Adriamycin was 0.29 and the tumor rate was 0.74. For 156 patients treated with Epodyl, the recurrence rate was 0.29 and the tumor rate was 0.57. This difference was not statistically significant. For 70 patients who received transurethral resection alone, the recurrence rate was 0.65 and the tumor rate, 2.04. In protocol 30,763, patients with good prognostic factors were treated with one single instillation of 4-epirubicin versus sterile water. After a mean follow-up period of 16 months, in 190 patients treated with 4-epirubicin the recurrence rate was 0.20 and the tumor rate was 0.35; in 196 patients treated with sterile water, the recurrence rate was 0.37 and the tumor rate was 0.65 (P = 0.0001). Adriamycin and 4-epirubicin were efficacious, and severe side effects were not encountered. The superiority of Adriamycin over Epodyl could not be proven.

Administration, Intravesical

Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group.

A total of 356 patients with recurrent superficial transitional cell carcinoma of the bladder was entered in a randomized clinical trial to compare intravesical thiotepa, doxorubicin and cisplatin with respect to the recurrence rate and disease-free interval. After complete transurethral resection of all visible lesions, the drugs were administered weekly for 4 weeks and monthly for 11 months. The recurrence rates per year were 0.50 for thiotepa, 0.54 for doxorubicin and 0.58 for cisplatin. Of 266 patients (mean followup 41 months) 35 reported an increase in T category and 19 of them had distant metastases. No association between treatment and progression was noted. Thus, there is no difference among treatments with respect to efficacy. However, severe anaphylactic reactions were observed in the cisplatin arm and chemical cystitis was more frequently reported in patients who received doxorubicin.

Administration, Intravesical